HCW Biologics to file IND for HCW11-018b in first half of 2027

HCW Biologics (HCWB) announced major development regarding its tetra-valent, second-generation T-Cell Engager Program based on its TRBC platform technology, which was presented at the poster session at the American Association of Cancer Research Annual Meeting 2026. “HCW11-018b exhibits remarkable anti-tumor activities with high tolerability in animal models. With its streamlined GMP manufacturing process, the Company is vigorously -pursuing the clinical development path for solid tumors with particular focus on pancreatic and ovarian cancer. The IND application is projected to be filed in the first half of 2027,” said Hing Wong, founder and CEO.